The global hepatitis c treatment market accounted for US$ 25.8 Bn in 2018 and burgeoning over the forthcoming years. Some of the key factors favoring the market growth include supportive government’s initiatives to control hepatitis C infection by various countries and increase in the occurrence of hepatitis c infection. However, high cost of the drugs, strict regulatory norms and side effects of available drugs are some factors hindering the market growth. In addition, high growth from emerging economies provides huge growth opportunity for the market.

 

Global hepatitis c treatment market segmented on the basis of drug class, route of administration, distribution channel and region.

 

For request sample : https://www.precisionbusinessinsights.com/request-sample?product_id=16289

 

Interferons dominate the Global Hepatitis C Treatment Market

Based on drug class, global hepatitis c treatment market is polymerase inhibitors, NS5A inhibitors, interferons, HCV protease inhibitors and combination therapy. Interferons held considerable market growth during estimated period. For over years now, interferon has been used for the treatment of hepatitis C. Interferon treatment for hepatitis C would typically last 24–48 weeks (6–12 months). Interferon, any of several related proteins that are produced by the body’s cells as a defensive response to viruses. They are important modulators of the immune response. The various forms of interferon are the body’s most rapidly produced and important defense against viruses. Interferons caused many long-term side effects partly because of this long treatment time.

 

North America Leads the Global Hepatitis C Treatment market

PBI’s global hepatitis c treatment market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. According to regional analysis. North America accounted for larger revenue share in global hepatitis c treatment market with considerable CAGR. The growth in this region can be attributed to increase in spending’s on research and development activities and rise in the awareness by the vendors regarding the use of innovative products. Further, Europe held significant market share during estimated period owing to change in the lifestyle of the people and rise in the geriatric population.

 

Strategic Approvals are the Key Strategies Adopted by Market Players

Global hepatitis c treatment market further reveals that the key players increasingly adopting strategies such as launch of newer products, frequent product approvals, and long term alliance to improve market revenue share and gaining significant geographic presence across the region. For Instance, In August 2017, AbbVie received FDA approval for Mavyret (glecaprevir/pibrentasvir), for the chronic hepatitis C virus (HCV) infection in all major genotypes (GT1-6).

 

Key player’s profiles in the report are GlaxoSmithKline, plc. (U.K.), Bristol-Myers Squibb (U.S), F. Hoffmann- La Roche Ltd. (Switzerland), Merck & Co, Inc. (U.S), Johnson & Johnson Services, Inc. (U.S.), Gilead Sciences (U.S.), AbbVie Inc. (U.S.), Vertex Pharmaceuticals Inc. (U.S.) and Kadmon Holdings, Inc. (U.S.)

 

Precision Business Insights (PBI) in its report titled “Global Hepatitis C Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025” assesses the market performance over seven years forecast period over 2019-2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period. Moreover, the report also includes the total revenue and volume for the market.

 

Detailed Segmentation

 

By Drug Class

• Polymerase Inhibitors
• NS5A Inhibitors
• Interferons
• HCV protease inhibitors
• Combination Therapy

 

By Route of Administration  

• Oral
• Parenteral

 

By Distribution Channel        

• Retail Pharmacies
• Hospital Pharmacies
• Others          

 

By Geography

• North America

• U.S
• Canada

• Europe

• Germany
• France
• U.K
• Italy
• Spain
• Russia
• Poland
• Rest of Europe

• Asia-Pacific

• Japan
• China
• India
• Australia & New Zealand
• ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
• South Korea
• Rest of Asia-Pacific

• Latin America

• Brazil
• Mexico
• Argentina
• Rest of Latin America

• Middle East and Africa (MEA)

• Gulf Cooperation Council (GCC) Countries
• Israel
• South Africa
• Rest of MEA

 

For more information: https://www.precisionbusinessinsights.com/market-reports/global-hepatitis-c-treatment-market/

 

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customized market research services based on our client needs.

 

Kemp House,

152 – 160 City Road,

London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US): +1-866-598-1553

Website @ https://www.precisionbusinessinsights.com